Oncology
 |
|
20 september 2019 09:00:17 |
| Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancer (British Journal of Cancer) |
|
Tweet |
| 224 viewsCategory: Oncology |
 Correction: Glioma-associated human endothelial cell-derived extracellular vesicles specifically promote the tumourigenicity of glioma stem cells via CD9 (Oncogene)Inactivation of PP2A by a recurrent mutation drives resistance to MEK inhibitors (Oncogene) 
|
| blog comments powered by Disqus |
MyJournals.org
The latest issues of all your favorite science journals on one page
The latest issues of all your favorite science journals on one page
